| Literature DB >> 35500368 |
Janna Krahe1, Imis Dogan1, Claire Didszun2, Shahram Mirzazade2, Alexa Haeger1, Nadim Joni Shah3, Ilaria A Giordano4, Thomas Klockgether4, Guillaume Madelin5, Jörg B Schulz1, Sandro Romanzetti1, Kathrin Reetz6.
Abstract
In patients with Friedreich ataxia, structural MRI is typically used to detect abnormalities primarily in the brainstem, cerebellum, and spinal cord. The aim of the present study was to additionally investigate possible metabolic changes in Friedreich ataxia using in vivo sodium MRI that may precede macroanatomical alterations, and to explore potential associations with clinical parameters of disease progression. Tissue sodium concentration across the whole brain was estimated from sodium MRI maps acquired at 3 T and compared between 24 patients with Friedreich ataxia (21-57 years old, 13 females) and 23 controls (21-60 years old, 12 females). Tensor-based morphometry was used to assess volumetric changes. Total sodium concentrations and volumetric data in brainstem and cerebellum were correlated with clinical parameters, such as severity of ataxia, activity of daily living and disability stage, age, age at onset, and disease duration. Compared to controls, patients showed reduced brain volume in the right cerebellar lobules I-V (difference in means: -0.039% of total intracranial volume [TICV]; Cohen's d = 0.83), cerebellar white matter (WM) (-0.105%TICV; d = 1.16), and brainstem (-0.167%TICV; d = 1.22), including pons (-0.102%TICV; d = 1.00), medulla (-0.036%TICV; d = 1.72), and midbrain (-0.028%TICV; d = 1.05). Increased sodium concentration was additionally detected in the total cerebellum (difference in means: 2.865 mmol; d = 0.68), and in several subregions with highest effect sizes in left (5.284 mmol; d = 1.01) and right cerebellar lobules I-V (5.456 mmol; d = 1.00), followed by increases in the vermis (4.261 mmol; d = 0.72), and in left (2.988 mmol; d = 0.67) and right lobules VI-VII (2.816 mmol; d = 0.68). In addition, sodium increases were also detected in all brainstem areas (3.807 mmol; d = 0.71 to 5.42 mmol; d = 1.19). After controlling for age, elevated total sodium concentrations in right cerebellar lobules IV were associated with younger age at onset (r = -0.43) and accordingly with longer disease duration in patients (r = 0.43). Our findings support the potential of in vivo sodium MRI to detect metabolic changes of increased total sodium concentration in the cerebellum and brainstem, the key regions in Friedreich ataxia. In addition to structural changes, sodium changes were present in cerebellar hemispheres and vermis without concomitant significant atrophy. Given the association with age at disease onset or disease duration, metabolic changes should be further investigated longitudinally and in larger cohorts of early disease stages to determine the usefulness of sodium MRI as a biomarker for early neuropathological changes in Friedreich ataxia and efficacy measure for future clinical trials.Entities:
Keywords: Biomarkers; Friedreich ataxia; Magnetic resonance imaging; Metabolic imaging; Sodium MRI
Mesh:
Substances:
Year: 2022 PMID: 35500368 PMCID: PMC9065922 DOI: 10.1016/j.nicl.2022.103025
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.891
Demographic and clinical characteristics of the total sample.
| N (%) | 24 (100 %) | 23 (100 %) |
| Female/Male (%) | 13 (54%) / 11 (46%) | 12 (52%) / 11 (48%) |
| Age (years) | 35.58 ± 11.07 | 35.17± 12.04 |
| Age of onset (years) | 16.29 ± 6.82 | – |
| Typical onset (%) | 21 (88 %) | – |
| Late onset (%) | 3 (12 %) | – |
| Disease duration (years) | 19.29 ± 9.23 | – |
| GAA repeats: | ||
| Allele 1 | 518.50 ± 217.08 | 33.71 ± 13.89 |
| Allele 2 | 805.79 ± 194.83 | 33.71 ± 13.89 |
| Point mutation (%) | 1 (4 %)a | 0 |
| SARA score | 17.79 ± 9.12 | 0.03 ± 0.12 |
| ADL score | 13.13 ± 6.87 | 0.17 ± 0.71 |
| Disability stage | 4.58 ± 1.25 | 0 |
| Ambulatory (%) | 17 (71 %) | 23 (100%) |
| Non-ambulatory (%) | 7 (29 %) | 0 |
Data are presented as mean ± standard deviation or n (%) ; N = sample size; typical onset = age at onset ≤ 24 years; late onset = age at onset ≥ 25 years; GAA1 / GAA2 = GAA-repeat length on allele 1 / allele 2: data are missing for 7 controls; apoint mutation = mutation of start codon ATG; SARA = Scale for the assessment and rating of ataxia (maximal severity-score 40): data are missing for 6 controls; ADL = Activity of daily living scale (maximal severity-score 36): data are missing for 6 controls; disability stage = spinocerebellar degeneration functional score (SDFS; maximal severity-score 7); ambulatory = SDFS 1 – 5 (no functional handicap but signs at examination – walking with two sticks); non-ambulatory = SDFS 6 – 7 (unable to walk, requiring wheelchair – confined to bed).
Fig. 1Visualization of group differences in brain volume (orange) and total sodium concentration (blue) between patients with Friedreich ataxia and controls. Group differences in brain volume (patients < controls, p < 0.05; highlighted in orange) calculated using tensor-based morphometry. Overlayed group differences in total sodium concentration (patients > controls, p < 0.05; highlighted in blue) calculated using voxel-based permutation analysis performed with BROCCOLI. Both whole-brain analyses showed significant changes in cerebellum and brainstem. The colors show differences significant at p < 0.05. The brain slices shown represent the range between the respective endpoints where the differences of total sodium concentration are still visible. Abbreviations: Sagittal (L/R) = left/rigth hemisphere sagittal section. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Brain volume and tissue sodium concentration of cerebellum and brainstem in patients with Friedreich ataxia compared to controls.
| L / R | 1.606 ± 0.127 | 1.773 ± 0.145 | 45.704 ± 5.111 | 41.566 ± 3.628 | |||
| Pons | L / R | 0.952 ± 0.097 | 1.054 ± 0.107 | 44.056 ± 5.143 | 40.306 ± 3.849 | ||
| Medulla | L / R | 0.299 ± 0.021 | 0.335 ± 0.021 | 44.703 ± 6.366 | 40.896 ± 4.026 | ||
| Midbrain | L / R | 0.356 ± 0.025 | 0.384 ± 0.029 | 51.238 ± 4.966 | 45.818 ± 4.099 | ||
| L / R | 10.117 ± 0.798 | 10.182 ± 0.638 | 0.09 | 42.511 ± 4.344 | 39.646 ± 4.074 | ||
| I-V | L | 0.540 ± 0.057 | 0.573 ± 0.044 | 0.65+ | 55.243 ± 5.166 | 49.959 ± 5.278 | |
| R | 0.572 ± 0.057 | 0.611 ± 0.035 | 54.720 ± 5.633 | 49.264 ± 5.230 | |||
| VI-VII | L | 2.752 ± 0.261 | 2.730 ± 0.215 | 0.09 | 40.939 ± 4.369 | 37.951 ± 4.488 | |
| R | 2.734 ± 0.258 | 2.752 ± 0.183 | 0.08 | 40.889 ± 4.310 | 38.073 ± 3.897 | ||
| VIII-X | L | 1.008 ± 0.092 | 0.967 ± 0.099 | 0.44 | 39.702 ± 4.223 | 37.610 ± 4.698 | 0.47 |
| R | 0.995 ± 0.102 | 0.942 ± 0.099 | 0.53 | 38.685 ± 5.247 | 37.789 ± 4.443 | 0.18 | |
| Vermis | L / R | 0.437 ± 0.044 | 0.424 ± 0.037 | 0.32 | 54.382 ± 6.117 | 50.121 ± 5.696 | |
| Cerebellar WM | L / R | 1.078 ± 0.101 | 1.183 ± 0.079 | 38.965 ± 4.661 | 36.494 ± 4.158 | 0.56 | |
| Frontal lobe | L | 13.309 ± 0.387 | 13.416 ± 0.536 | 0.23 | 40.903 ± 4.613 | 39.623 ± 4.869 | 0.27 |
| R | 13.183 ± 0.334 | 13.432 ± 0.622 | 0.50 | 41.420 ± 4.611 | 39.965 ± 4.809 | 0.31 | |
| Temporal lobe | L | 4.965 ± 0.210 | 4.903 ± 0.265 | 0.26 | 40.642 ± 4.128 | 39.815 ± 3.956 | 0.20 |
| R | 5.090 ± 0.241 | 5.059 ± 0.189 | 0.14 | 40.745 ± 3.973 | 39.754 ± 3.828 | 0.25 | |
| Parietal lobe | L | 5.645 ± 0.278 | 5.699 ± 0.245 | 0.21 | 44.697 ± 4.942 | 43.158 ± 4.863 | 0.31 |
| R | 5.791 ± 0.236 | 5.795 ± 0.214 | 0.02 | 44.572 ± 4.352 | 42.825 ± 4.854 | 0.38 | |
| Occipital lobe | L | 2.537 ± 0.286 | 2.502 ± 0.277 | 0.12 | 43.079 ± 4.229 | 41.451 ± 4.063 | 0.39 |
| R | 2.312 ± 0.280 | 2.235 ± 0.237 | 0.30 | 43.323 ± 4.268 | 42.102 ± 4.265 | 0.29 | |
Data are presented as mean ± standard deviation. Brain volumes are adjusted for total intracranial volume (TICV) and displayed in % (TICV = 100%). Significant group differences between patients with Friedreich ataxia (N = 24) and controls (N = 23) at * (adjusted for multiple testing using the Benjamini-Hochberg procedure within the brainstem and cerebellar regions, respectively); +not significant after Benjamini-Hochberg procedure. Criteria for the evaluation of effect sizes (Cohen’s d): 0.20 = small effect, 0.50 = medium effect, 0.80 = large effect. Abbreviations: L = left; R = right; TSC = total sodium concentration.
Fig. 2Group comparisons in brain volume and total sodium concentration in cerebellar and brainstem subregions between patients with Friedreich ataxia ( Group differences in brain volumes. (B) Group differences in total sodium concentration. Data of brain volumes are adjusted for total intracranial volume (TICV) and displayed as percentage; *p < 0.05, **p < 0.01 or ***p < 0.001 (significance thresholds); + not significant after Benjamini-Hochberg procedure (p greater than 0.05). Abbreviations: FRDA = Friedreich ataxia; L = left hemisphere; R = right hemisphere; I-X = cerebellar lobules I-X; cWM = cerebellar white matter.
Fig. 3Correlations of MRI data with clinical variables in patients with Friedreich ataxia ( (A) Correlations with brain volume data. (B) Correlations with total tissue sodium concentration (TSC). Abbreviations: SARA = scale for the assessment and rating of ataxia; ADL = activity of daily living scale; TICV = total intracranial volume.